Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients

Figure 1 Receiver operating characteristics curves of the multivariate model for the 5-yr, 8-yr and 10-yr post-transplant cutaneous squamous cell carcinoma prediction. A: The derivation set; B: The validation set. AUC: Area under the curve.

Figure 2 Predicted vs observed probabilities of developing cSCC 5 yr after transplant in different risk groups: very low-risk group (score ≤ 5), low-risk group (score = 6), medium-risk group (score = 7), high-risk group (score ≥ 8). cSCC: Cutaneous squamous cell carcinoma.

Figure 3 Cumulative cSCC-free survival curves for different risk groups. cSCC: Cutaneous squamous cell carcinoma.

Figure 4 Cumulative survival curves for heart transplant recipients with cSCC and with no cancer. cSCC: Cutaneous squamous cell carcinoma.

Figure 5 Receiver operating characteristics curves of the multivariate model without OKT3 and daclizumab for the 5-yr, 8-yr and 10-yr post-transplant cutaneous squamous cell carcinoma prediction. A: The derivation set; B: The validation set. AUC: Area under the curve.

Figure 6 Predicted vs observed probabilities of developing cSCC 5 yr after transplant in different risk groups where patients were divided using the scoring system without OKT3 and daclizumab: very low-risk group (score ≤ 5), low-risk group (score = 6), medium-risk group (score = 7), high-risk group (score ≥ 8). cSCC: Cutaneous squamous cell carcinoma.

Figure 7 Cumulative cSCC-free survival curves for different risk groups where patients were divided using the scoring system without OKT3 and daclizumab. cSCC: Cutaneous squamous cell carcinoma.